MyAmici is partnering with Young Epilepsy: Standing with Children and Young People Living with Epilepsy

MyAmici is partnering with Young Epilepsy: Standing with Children and Young People Living with Epilepsy article thumbnail image

MyAmici is partnering with Young Epilepsy: Standing with Children and Young People Living with Epilepsy

MyAmici is proud to announce Young Epilepsy as our chosen charity partner for 2026. Young Epilepsy is dedicated to supporting children and young people with epilepsy, ensuring their voices are heard and their experiences are understood in schools, healthcare settings, and wider society. Childhood epilepsy can be frightening, isolating, and often misunderstood, and the charity works tirelessly to change that by raising awareness and challenging stigma. 

Why our partnership with Young Epilepsy matters

A key part of Young Epilepsy’s mission is to stand alongside children and young people with epilepsy and their families at every stage of their journey. They provide practical support, information, and guidance to help them navigate everyday life, from managing seizures and treatments to dealing with the impact on education, friendships, and mental health. Through initiatives such as youth support, they help young people thrive at school, college, and university, making sure they are not left behind because of their condition. 

 

Young Epilepsy is also deeply involved in groundbreaking health services and research that aim to improve how epilepsy is diagnosed and treated. Working with leading research partners, they are actively looking for answers to better understand the causes of epilepsy, refine diagnostic pathways, and develop more effective, personalized treatments. By supporting this work, MyAmici is helping to advance vital science that can transform outcomes for thousands of children and young people now and in the future. 

 

This partnership is especially meaningful for the MyAmici team. In October, our colleague Kevin Barclay raised funds for Young Epilepsy after his 12‑year‑old daughter received her epilepsy diagnosis, bringing the charity’s work very close to home for all of us. Kevin’s efforts highlighted just how important the right support and information can be for families suddenly facing epilepsy, and it inspired us to make Young Epilepsy our focus for the year ahead. Throughout 2026, we will be organising fundraising activities, awareness campaigns, and team events to back their vital work and keep epilepsy firmly on the agenda. 

Celebrating last years success...

We also want to take a moment to celebrate what we achieved together last year. In 2025, MyAmici partnered with Beatson Cancer Charity, and the year was filled with amazing events, teamwork, and generosity across the company. From fundraising challenges to team initiatives, everyone played a part in supporting people and families affected by cancer, and together we raised an incredible £2,437. That collective effort showed what our team can do when we rally behind a cause, and we are hugely grateful to everyone who contributed. 

 

Building on the success of our partnership with Beatson Cancer Charity, we are excited to channel that same energy and commitment into supporting Young Epilepsy in 2026. Our goal is to go even bigger and better this year raising more funds, engaging more colleagues, and shining a brighter light on the experiences of children and young people living with epilepsy. We look forward to sharing updates on our progress, our fundraising milestones, and the impact that, together, we can help Young Epilepsy deliver. 

About MyAmici

MyAmici is a comprehensive LabOps platform designed to help biotech, medtech, and life-science organizations operate smarter, safer, and more efficiently.

With integrated capabilities across procurement, inventory management, equipment, HSE compliance, and financial controls, MyAmici equips teams with the tools they need to accelerate scientific progress while maintaining operational excellence. The company supports customers across the UK, EU, Switzerland, and the United States.